Highlighting Research Progress in Tau-Targeting Therapy for Alzheimer Disease: Diana Gallagher, MD
Written by
Neurology Live
Published
0
comments
0
min
At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]